tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2023 Aug 12;10(8)
fad431.
doi: 10.1093/ofid/ofad431. eCollection 2023 Aug. Humoral Immune Response to Messenger RNA Coronavirus Disease 2019 Vaccination Among Children Aged 5-11 Years in a Multisite Prospective Cohort Study, September 2021-September 2022
Zoe L Lyski[SUP] 1 [/SUP], Cynthia Porter[SUP] 2 [/SUP], Jennifer L Uhrlaub[SUP] 1 [/SUP], Katherine D Ellingson[SUP] 2 [/SUP], Zuha Jeddy[SUP] 3 [/SUP], Lisa Gwynn[SUP] 4 [/SUP], Patrick Rivers[SUP] 5 [/SUP], Ryan Sprissler[SUP] 6 [/SUP], Kurt T Hegmann[SUP] 7 [/SUP], Melissa Coughlin[SUP] 8 [/SUP], Ashley Fowlkes[SUP] 9 [/SUP], James Hollister[SUP] 2 [/SUP], Lindsay LeClair[SUP] 3 [/SUP], Josephine Mak[SUP] 8 [/SUP], Shawn C Beitel[SUP] 2 [/SUP], Sammantha Fuller[SUP] 3 [/SUP], Lauren Grant[SUP] 9 [/SUP], Gabriella Newes-Adeyi[SUP] 3 [/SUP], Young M Yoo[SUP] 9 [/SUP], Lauren Olsho[SUP] 3 [/SUP], Jefferey L Burgess[SUP] 2 [/SUP], Alberto Caban-Martinez[SUP] 4 [/SUP], Sarang Yoon[SUP] 7 [/SUP], Amadea Britton[SUP] 8 [/SUP], Manjusha Gaglani[SUP] 10 [/SUP], Karen Lutrick[SUP] 5 [/SUP]
Affiliations
Background: The PROTECT study is a longitudinal cohort study initiated in July 2021 with weekly testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 4 states: Arizona, Florida, exas, and Utah. This study aims to examine vaccine-elicited antibody response against postvaccination SARS-CoV-2 infections.
Methods: Children aged 5-11 years had serum collected 14-59 days after their second dose of monovalent Pfizer-BioNTech coronavirus disease 2019 messenger RNA vaccine. Vaccine-elicited antibodies were measured using the area under the curve (AUC) and end-point titer using enzyme-linked immunosorbent assay (receptor-binding domain [RBD] and S2) and surrogate neutralization assays against ancestral (WA1) and Omicron (BA.2).
Results: 79 vaccinated participants (33 [41.7%] female; median age, 8.8 years [standard deviation, 1.9 years]), 48 (60.8%) were from Tucson, Arizona; 64 (81.0%) were non-Hispanic white; 63 (80.8%) attended school in person; 68 (86.1%) did not have any chronic conditions; and 47 (59.5%) were infected after vaccination. Uninfected children had higher AUCs against WA1 (P = .009) and Omicron (P = .02). The geometric mean and surrogate neutralization titer above the limit of detection was 346.0 for WA1 and 39.7 for Omicron, an 8.7-fold decrease (P < .001). After adjustment of covariates in the WA1-specific model, we observed a 47% reduction in the odds of postvaccination infection for every standard deviation increase in RBD AUC (aOR, 0.53 [95% confidence interval, .29-.97) and a 69% reduction in the odds of infection for every 3-fold increase in RBD end titer (0.31 [.06-1.57]).
Conclusions: Children with higher antibody levels experienced a lower incidence of postvaccination SARS-CoV-2 infection.
. 2023 Aug 12;10(8)
fad431.doi: 10.1093/ofid/ofad431. eCollection 2023 Aug. Humoral Immune Response to Messenger RNA Coronavirus Disease 2019 Vaccination Among Children Aged 5-11 Years in a Multisite Prospective Cohort Study, September 2021-September 2022
Zoe L Lyski[SUP] 1 [/SUP], Cynthia Porter[SUP] 2 [/SUP], Jennifer L Uhrlaub[SUP] 1 [/SUP], Katherine D Ellingson[SUP] 2 [/SUP], Zuha Jeddy[SUP] 3 [/SUP], Lisa Gwynn[SUP] 4 [/SUP], Patrick Rivers[SUP] 5 [/SUP], Ryan Sprissler[SUP] 6 [/SUP], Kurt T Hegmann[SUP] 7 [/SUP], Melissa Coughlin[SUP] 8 [/SUP], Ashley Fowlkes[SUP] 9 [/SUP], James Hollister[SUP] 2 [/SUP], Lindsay LeClair[SUP] 3 [/SUP], Josephine Mak[SUP] 8 [/SUP], Shawn C Beitel[SUP] 2 [/SUP], Sammantha Fuller[SUP] 3 [/SUP], Lauren Grant[SUP] 9 [/SUP], Gabriella Newes-Adeyi[SUP] 3 [/SUP], Young M Yoo[SUP] 9 [/SUP], Lauren Olsho[SUP] 3 [/SUP], Jefferey L Burgess[SUP] 2 [/SUP], Alberto Caban-Martinez[SUP] 4 [/SUP], Sarang Yoon[SUP] 7 [/SUP], Amadea Britton[SUP] 8 [/SUP], Manjusha Gaglani[SUP] 10 [/SUP], Karen Lutrick[SUP] 5 [/SUP]
Affiliations
- PMID: 37663086
- PMCID: PMC10468733
- DOI: 10.1093/ofid/ofad431
Background: The PROTECT study is a longitudinal cohort study initiated in July 2021 with weekly testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 4 states: Arizona, Florida, exas, and Utah. This study aims to examine vaccine-elicited antibody response against postvaccination SARS-CoV-2 infections.
Methods: Children aged 5-11 years had serum collected 14-59 days after their second dose of monovalent Pfizer-BioNTech coronavirus disease 2019 messenger RNA vaccine. Vaccine-elicited antibodies were measured using the area under the curve (AUC) and end-point titer using enzyme-linked immunosorbent assay (receptor-binding domain [RBD] and S2) and surrogate neutralization assays against ancestral (WA1) and Omicron (BA.2).
Results: 79 vaccinated participants (33 [41.7%] female; median age, 8.8 years [standard deviation, 1.9 years]), 48 (60.8%) were from Tucson, Arizona; 64 (81.0%) were non-Hispanic white; 63 (80.8%) attended school in person; 68 (86.1%) did not have any chronic conditions; and 47 (59.5%) were infected after vaccination. Uninfected children had higher AUCs against WA1 (P = .009) and Omicron (P = .02). The geometric mean and surrogate neutralization titer above the limit of detection was 346.0 for WA1 and 39.7 for Omicron, an 8.7-fold decrease (P < .001). After adjustment of covariates in the WA1-specific model, we observed a 47% reduction in the odds of postvaccination infection for every standard deviation increase in RBD AUC (aOR, 0.53 [95% confidence interval, .29-.97) and a 69% reduction in the odds of infection for every 3-fold increase in RBD end titer (0.31 [.06-1.57]).
Conclusions: Children with higher antibody levels experienced a lower incidence of postvaccination SARS-CoV-2 infection.